Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2005-04-12
2005-04-12
LeGuyader, John L. (Department: 1635)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S006120, C435S091100, C435S091500, C536S023100, C536S024310, C536S024500
Reexamination Certificate
active
06878547
ABSTRACT:
The invention relates to specific, optionally modified oligonucleotides with a length of up to 17 nucleotides. Said oligonucleotides correspond to segments of tenascin-coding sequences or can bind to these sequences. The invention also relates to the production and use of the oligonucleotides, for example for the specific inhibition of the expression of tenascin and for producing medicaments used to treat vitiligo.
REFERENCES:
patent: 5217867 (1993-06-01), Evans et al.
patent: 5594122 (1997-01-01), Friesen
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 6013639 (2000-01-01), Peyman et al.
patent: 0-564801 (1993-02-01), None
patent: WO-9421664 (1993-03-01), None
patent: WO 9421664 (1994-09-01), None
Robert L. Cleek, Inhibition of smooth muscle cell growth in vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles, Journal of Boimedical Materials Research, vol. 35, (1997) pp. 525-530.*
W. James, Towards gene-inhibition therapy; a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes. Antiviral Chemistry & Chemotherapy (1991) 2(4) pp 191-214.*
Natalie Milner et al., Selecting effective antisense reagents on combinatorial oligonucleotide arrays, Nature Biotechnology vol. 15, Jun. 1997 pp 537-541.*
Stanley T Crooke. Antisense Research and Application, pp 1-50.*
Andrea D. Branch, A good antisense molecule is hard to find. TIBS 23—Feb. 1998 pp. 45-50.*
Karen Pihl-Carey, Isis To Reconstructure As Crohn's Disease Drug Fails In Phase III, Bioworld Today, Vol. 10, No. 239, pp.1-2.*
Giorgio Palu'In pursuit of new developments for gene therapy of human diseases, Journal of Biotechnology 68 (1999) pp. 1-13.*
Robert L. Cleek, Polymeric Delivery of Inhibitors of Smooth Muscle Cell Proliferation (Restenosis). vol. 59/03-B of Dissertation Abstracts International, p. 1227 93 pages.*
“Cancer Drugs in Clinical Development ISIS 3521” www.isip.com/products/3521gi.htm, Oct. 16, 2001.
“Cancer Drugs in Clinical Development ISIS 5132” www.isip.com/products/5132gi.htm, Oct. 16, 2001.
“Drug Approvals for Aug. 1998” www.fda.gov/cder/da/da0898.htm, Oct. 16, 2001.
“ISIS 2922” www.aegis.org/pubs/drugs/78.htm, Oct. 16, 2001.
Woolf, T.M., et al., “Specificity of antisense oligonucleotides in vivo.” Proc. Natl. Acad. Sci., USA, vol. 89, pp. 7305-7309 (1992).
Peyman, A., et al., “Minimally modified oligonucleotides—combination of end-capping and pyrimidine-protection,” Biol. Chem. Hoppe-Seyler, vol. 377, pp. 67-70 (1996).
Le Poole, I.C., et al., “Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion,” British Journal of Dermatology, vol. 137, No. 2, pp. 171-178 (1997).
O'Donnell, D.B., et al., “Tenascin is abundant in the skin of vitiligo patients,” J. Invest. Dermatol., vol. 98, No. 4, p. 620, Abstract 409 (1992).
Torrence, P.F., et al., “Targeting RNA for degradation with a (2′-5′)oligoadenylate-antisense chimera.” Proc. Natl. Acad. Sci., USA, vol. 90, pp. 1300-1304 (1993).
Ortigao, J.F.R., et al., “Antisense effect of oligodeoxynucleotides with inverted terminal internucleotidic linkages: a minimal modification protecting against nucleotide degradation,” Antisense Research and Dev., vol. 2, pp. 129-146 (1992).
Peyman Anuschirwan
Weiser Caroline
Aventis Pharma Deutschland GmbH
LeGuyader John L.
Zara Jane
LandOfFree
Antisense oligonucleotides against tenascin for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides against tenascin for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides against tenascin for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3377775